NDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZOCOR (simvastatin) by Merck & Co. is hydroxymethylglutaryl-coa reductase inhibitors [moa]. Approved for hypercholesterolemia, cardiovascular disease, dyslipidemia. First approved in 1991.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOCOR (simvastatin) is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol production in the liver by blocking a key enzyme. It is indicated for hypercholesterolemia, cardiovascular disease prevention, and dyslipidemia management across multiple chronic conditions. The drug works by inhibiting hepatic cholesterol synthesis, thereby lowering LDL-C and triglycerides while modestly raising HDL-C.
$2MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Medicare Part D spending; brand team focused on maintaining generic transition strategy and cost-containment initiatives.
Mechanism of Action
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Class:
HMG-CoA Reductase Inhibitor
Indications (3)
Worked on ZOCOR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.